These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1329481)

  • 1. Importance of long-acting angiotensin-converting enzyme inhibitors for congestive heart failure.
    Giles TD
    Am J Cardiol; 1992 Oct; 70(10):98C-101C. PubMed ID: 1329481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition, the sympathetic nervous system, and congestive heart failure. The Australian Zestril (Lisinopril) Study Group.
    Sloman G
    Am J Cardiol; 1992 Oct; 70(10):113C-118C. PubMed ID: 1329466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.
    Coats AJ; Adamopoulos S
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):685-92. PubMed ID: 7873465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
    Sigurdsson A; Swedberg K
    Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of prolonged angiotensin-converting enzyme inhibition in congestive heart failure.
    Giles TD
    Cardiology; 1991; 79 Suppl 1():16-21. PubMed ID: 1680559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
    Lee AF; MacFadyen RJ; Struthers AD
    Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of lisinopril on serum catecholamine concentrations both at rest and on exercise in patients with congestive cardiac failure. A double blind, placebo controlled, parallel group study.
    Fahy G; Deb B; Robinson K; Graham I
    Ir Med J; 1993; 86(4):134-5. PubMed ID: 8395488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with lisinopril in congestive heart failure. Focus on the older patient.
    Giles TD
    Drugs; 1990; 39 Suppl 2():17-22. PubMed ID: 2160883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment with lisinopril versus enalapril for congestive heart failure.
    Zannad F; van den Broek SA; Bory M
    Am J Cardiol; 1992 Oct; 70(10):78C-83C. PubMed ID: 1329478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
    Kubo SH
    Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.
    Gilbert EM; Sandoval A; Larrabee P; Renlund DG; O'Connell JB; Bristow MR
    Circulation; 1993 Aug; 88(2):472-80. PubMed ID: 8393389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuro-hormonal mechanisms in heart insufficiency--from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; de Faria DB
    Rev Port Cardiol; 1989 Feb; 8(2):129-48. PubMed ID: 2576635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting angiotensin-converting enzyme inhibition: once-daily lisinopril versus twice-daily captopril in mild-to-moderate heart failure.
    Bach R; Zardini P
    Am J Cardiol; 1992 Oct; 70(10):70C-77C. PubMed ID: 1329477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
    Langtry HD; Markham A
    Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition.
    Cohn JN
    Am J Cardiol; 1990 Oct; 66(11):2D-6D. PubMed ID: 2220601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuro-hormonal mechanisms in heart failure -- from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; da Faria DB
    Rev Port Cardiol; 2001 May; 20 Suppl 5():V-99-122; discussion V-123-5. PubMed ID: 11515306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.